CONTEXT: Recent studies disputed the widely promoted anti-aging effect of dehydroepiandrosterone (DHEA) supplementation; however, conflicting data exist on whether physiological DHEA supplementation enhances exercise training effects on body composition, physical performance, and cardiometabolic risk in healthy postmenopausal women. OBJECTIVE: The aim of this study was to determine whether 12 wk of DHEA supplementation (50 mg/d) in postmenopausal womenenhances exercise-related changes in body composition, physical performance, and cardiometabolic risk. DESIGN AND SETTING: This study was a 12-wk randomized double-blind, placebo-controlled trial and took place at the Mayo Clinic General Clinical Research Center (Rochester, MN). PARTICIPANTS: Thirty-one sedentary, postmenopausal, Caucasian women (mean +/- sem age 64.6 +/- 1.0 yr) completed the study. INTERVENTION: Participants were randomized to one of two 12-wk interventions: 1) exercise training plus 50 mg/d of DHEA (n = 17), or 2) exercise training plus placebo (n = 14). The exercise intervention consisted of both endurance (4 d/wk) and resistance (3 d/wk) exercise components. MAIN OUTCOME MEASURES: The main outcomes were measures of body composition, physical performance, and measures of cardiometabolic risk. RESULTS: DHEA treatment with exercise resulted in increases in circulating sulfated DHEA (650%), total testosterone (100%), estradiol (165%), estrone (85%), and IGF-I (30%) (all P < or = 0.05, for all within and between treatment comparisons). Although exercise training alone significantly improved physical performance, body composition, and insulin sensitivity, administration of DHEA provided no additional benefits. CONCLUSIONS: Twelve weeks of combined endurance and resistance training significantly improved body composition, physical performance, insulin sensitivity, and low-density lipoprotein cholesterol particle number and size, whereas DHEA had no additional benefits.
RCT Entities:
CONTEXT: Recent studies disputed the widely promoted anti-aging effect of dehydroepiandrosterone (DHEA) supplementation; however, conflicting data exist on whether physiological DHEA supplementation enhances exercise training effects on body composition, physical performance, and cardiometabolic risk in healthy postmenopausal women. OBJECTIVE: The aim of this study was to determine whether 12 wk of DHEA supplementation (50 mg/d) in postmenopausal women enhances exercise-related changes in body composition, physical performance, and cardiometabolic risk. DESIGN AND SETTING: This study was a 12-wk randomized double-blind, placebo-controlled trial and took place at the Mayo Clinic General Clinical Research Center (Rochester, MN). PARTICIPANTS: Thirty-one sedentary, postmenopausal, Caucasian women (mean +/- sem age 64.6 +/- 1.0 yr) completed the study. INTERVENTION: Participants were randomized to one of two 12-wk interventions: 1) exercise training plus 50 mg/d of DHEA (n = 17), or 2) exercise training plus placebo (n = 14). The exercise intervention consisted of both endurance (4 d/wk) and resistance (3 d/wk) exercise components. MAIN OUTCOME MEASURES: The main outcomes were measures of body composition, physical performance, and measures of cardiometabolic risk. RESULTS:DHEA treatment with exercise resulted in increases in circulating sulfated DHEA (650%), total testosterone (100%), estradiol (165%), estrone (85%), and IGF-I (30%) (all P < or = 0.05, for all within and between treatment comparisons). Although exercise training alone significantly improved physical performance, body composition, and insulin sensitivity, administration of DHEA provided no additional benefits. CONCLUSIONS: Twelve weeks of combined endurance and resistance training significantly improved body composition, physical performance, insulin sensitivity, and low-density lipoprotein cholesterol particle number and size, whereas DHEA had no additional benefits.
Authors: Samia Mora; Moyses Szklo; James D Otvos; Philip Greenland; Bruce M Psaty; David C Goff; Daniel H O'Leary; Mohammed F Saad; Michael Y Tsai; A Richey Sharrett Journal: Atherosclerosis Date: 2007-05 Impact factor: 5.162
Authors: Catherine M Jankowski; Pamela Wolfe; Sarah J Schmiege; K Sreekumaran Nair; Sundeep Khosla; Michael Jensen; Denise von Muhlen; Gail A Laughlin; Donna Kritz-Silverstein; Jaclyn Bergstrom; Richele Bettencourt; Edward P Weiss; Dennis T Villareal; Wendy M Kohrt Journal: Clin Endocrinol (Oxf) Date: 2018-12-09 Impact factor: 3.478
Authors: Ketan K Dhatariya; Laura J S Greenlund; Maureen L Bigelow; Prabin Thapa; Ann L Oberg; G Charles Ford; Jill M Schimke; K Sreekumaran Nair Journal: Mayo Clin Proc Date: 2008-11 Impact factor: 7.616